Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

High resolution analysis of the intracellular proteome of cervical cancer cell lines unveils novel regulators of cervical carcinogenesis.

Pappa KI, Lygirou V, Kontostathi G, Makridakis M, Vougas K, Sfakianakis A, Daskalakis G, Zoidakis J, Anagnou NP.

Oncol Rep. 2019 Aug 8. doi: 10.3892/or.2019.7269. [Epub ahead of print]

PMID:
31524267
2.

Short Term Results of Fibrin Gel Obtained from Cord Blood Units: A Preliminary in Vitro Study.

Mallis P, Gontika I, Dimou Z, Panagouli E, Zoidakis J, Makridakis M, Vlahou A, Georgiou E, Gkioka V, Stavropoulos-Giokas C, Michalopoulos E.

Bioengineering (Basel). 2019 Aug 2;6(3). pii: E66. doi: 10.3390/bioengineering6030066.

3.

Functional secretome analysis reveals Annexin-A1 as important paracrine factor derived from fetal mesenchymal stem cells in hepatic regeneration.

Zagoura D, Trohatou O, Makridakis M, Kollia A, Kokla N, Mokou M, Psaraki A, Eliopoulos AG, Vlahou A, Roubelakis MG.

EBioMedicine. 2019 Jul;45:542-552. doi: 10.1016/j.ebiom.2019.07.009. Epub 2019 Jul 12.

4.

Proteome-based classification of Nonmuscle Invasive Bladder Cancer.

Stroggilos R, Mokou M, Latosinska A, Makridakis M, Lygirou V, Mavrogeorgis E, Drekolias D, Frantzi M, Mullen W, Fragkoulis C, Stasinopoulos K, Papadopoulos G, Stathouros G, Lazaris AC, Makrythanasis P, Ntoumas K, Mischak H, Zoidakis J, Vlahou A.

Int J Cancer. 2019 Jul 8. doi: 10.1002/ijc.32556. [Epub ahead of print]

PMID:
31286493
5.

Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment.

Schanstra JP, Luong TT, Makridakis M, Van Linthout S, Lygirou V, Latosinska A, Alesutan I, Boehme B, Schelski N, Von Lewinski D, Mullen W, Nicklin S, Delles C, Feuillet G, Denis C, Lang F, Pieske B, Bascands JL, Mischak H, Saulnier-Blache JS, Voelkl J, Vlahou A, Klein J.

JCI Insight. 2019 May 16;4(10). pii: 125638. doi: 10.1172/jci.insight.125638. eCollection 2019 May 16.

6.

Applications of multiple reaction monitoring targeted proteomics assays in human plasma.

Kontostathi G, Makridakis M, Zoidakis J, Vlahou A.

Expert Rev Mol Diagn. 2019 Jun;19(6):499-515. doi: 10.1080/14737159.2019.1615448. Epub 2019 May 17.

PMID:
31057016
7.

Implications of the mitochondrial interactome of mammalian thioredoxin 2 for normal cellular function and disease.

Chasapis CT, Makridakis M, Damdimopoulos AE, Zoidakis J, Lygirou V, Mavroidis M, Vlahou A, Miranda-Vizuete A, Spyrou G, Vlamis-Gardikas A.

Free Radic Biol Med. 2019 Jun;137:59-73. doi: 10.1016/j.freeradbiomed.2019.04.018. Epub 2019 Apr 21.

PMID:
31018154
8.

Development and Validation of Multiple Reaction Monitoring (MRM) Assays for Clinical Applications.

Kontostathi G, Makridakis M, Bitsika V, Tsolakos N, Vlahou A, Zoidakis J.

Methods Mol Biol. 2019;1959:205-223. doi: 10.1007/978-1-4939-9164-8_14.

PMID:
30852825
9.

Proteomics based identification of KDM5 histone demethylases associated with cardiovascular disease.

Mokou M, Klein J, Makridakis M, Bitsika V, Bascands JL, Saulnier-Blache JS, Mullen W, Sacherer M, Zoidakis J, Pieske B, Mischak H, Roubelakis MG, Schanstra JP, Vlahou A.

EBioMedicine. 2019 Mar;41:91-104. doi: 10.1016/j.ebiom.2019.02.040. Epub 2019 Feb 28.

10.

Impairment of chaperone-mediated autophagy affects neuronal homeostasis through altered expression of DJ-1 and CRMP-2 proteins.

Brekk OR, Makridakis M, Mavroeidi P, Vlahou A, Xilouri M, Stefanis L.

Mol Cell Neurosci. 2019 Mar;95:1-12. doi: 10.1016/j.mcn.2018.12.006. Epub 2018 Dec 15.

PMID:
30562574
11.

Amelioration of desmin network defects by αB-crystallin overexpression confers cardioprotection in a mouse model of dilated cardiomyopathy caused by LMNA gene mutation.

Galata Z, Kloukina I, Kostavasili I, Varela A, Davos CH, Makridakis M, Bonne G, Capetanaki Y.

J Mol Cell Cardiol. 2018 Dec;125:73-86. doi: 10.1016/j.yjmcc.2018.10.017. Epub 2018 Oct 18.

PMID:
30342008
12.

Membrane proteomics of cervical cancer cell lines reveal insights on the process of cervical carcinogenesis.

Pappa KI, Christou P, Xholi A, Mermelekas G, Kontostathi G, Lygirou V, Makridakis M, Zoidakis J, Anagnou NP.

Int J Oncol. 2018 Nov;53(5):2111-2122. doi: 10.3892/ijo.2018.4518. Epub 2018 Aug 7.

PMID:
30106135
13.

Role of Cytosolic Serine Hydroxymethyl Transferase 1 (SHMT1) in Phosphate-Induced Vascular Smooth Muscle Cell Calcification.

Boehme B, Schelski N, Makridakis M, Henze L, Vlahou A, Lang F, Pieske B, Alesutan I, Voelkl J.

Kidney Blood Press Res. 2018;43(4):1212-1221. doi: 10.1159/000492248. Epub 2018 Aug 2.

14.

The family of 14-3-3 proteins and specifically 14-3-3σ are up-regulated during the development of renal pathologies.

Rizou M, Frangou EA, Marineli F, Prakoura N, Zoidakis J, Gakiopoulou H, Liapis G, Kavvadas P, Chatziantoniou C, Makridakis M, Vlahou A, Boletis J, Vlahakos D, Goumenos D, Daphnis E, Iatrou C, Charonis AS.

J Cell Mol Med. 2018 Sep;22(9):4139-4149. doi: 10.1111/jcmm.13691. Epub 2018 Jun 28.

15.

Fibulin-3 Attenuates Phosphate-Induced Vascular Smooth Muscle Cell Calcification by Inhibition of Oxidative Stress.

Luong TTD, Schelski N, Boehme B, Makridakis M, Vlahou A, Lang F, Pieske B, Alesutan I, Voelkl J.

Cell Physiol Biochem. 2018;46(4):1305-1316. doi: 10.1159/000489144. Epub 2018 Apr 18.

16.

Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease.

Lygirou V, Latosinska A, Makridakis M, Mullen W, Delles C, Schanstra JP, Zoidakis J, Pieske B, Mischak H, Vlahou A.

J Transl Med. 2018 Apr 17;16(1):104. doi: 10.1186/s12967-018-1476-9.

17.

Comparison of Urine and Plasma Peptidome Indicates Selectivity in Renal Peptide Handling.

Magalhães P, Pontillo C, Pejchinovski M, Siwy J, Krochmal M, Makridakis M, Carrick E, Klein J, Mullen W, Jankowski J, Vlahou A, Mischak H, Schanstra JP, Zürbig P, Pape L.

Proteomics Clin Appl. 2018 Sep;12(5):e1700163. doi: 10.1002/prca.201700163. Epub 2018 Apr 23.

PMID:
29611317
18.

Urinary peptidomics analysis reveals proteases involved in diabetic nephropathy.

Krochmal M, Kontostathi G, Magalhães P, Makridakis M, Klein J, Husi H, Leierer J, Mayer G, Bascands JL, Denis C, Zoidakis J, Zürbig P, Delles C, Schanstra JP, Mischak H, Vlahou A.

Sci Rep. 2017 Nov 9;7(1):15160. doi: 10.1038/s41598-017-15359-9.

19.

High Resolution Proteomic Analysis of the Cervical Cancer Cell Lines Secretome Documents Deregulation of Multiple Proteases.

Pappa KI, Kontostathi G, Makridakis M, Lygirou V, Zoidakis J, Daskalakis G, Anagnou NP.

Cancer Genomics Proteomics. 2017 Nov-Dec;14(6):507-521. Review.

20.

Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.

Latosinska A, Mokou M, Makridakis M, Mullen W, Zoidakis J, Lygirou V, Frantzi M, Katafigiotis I, Stravodimos K, Hupe MC, Dobrzynski M, Kolch W, Merseburger AS, Mischak H, Roubelakis MG, Vlahou A.

Oncotarget. 2017 Apr 20;8(41):69435-69455. doi: 10.18632/oncotarget.17279. eCollection 2017 Sep 19.

21.

GeLC-MS: A Sample Preparation Method for Proteomics Analysis of Minimal Amount of Tissue.

Makridakis M, Vlahou A.

Methods Mol Biol. 2018;1788:165-175. doi: 10.1007/7651_2017_76.

PMID:
28994030
22.

Proteomic Analysis of Normal and Cancer Cervical Cell Lines Reveals Deregulation of Cytoskeleton-associated Proteins.

Pappa KI, Lygirou V, Kontostathi G, Zoidakis J, Makridakis M, Vougas K, Daskalakis G, Polyzos A, Anagnou NP.

Cancer Genomics Proteomics. 2017 Jul-Aug;14(4):253-266.

23.

Cervical Cancer Cell Line Secretome Highlights the Roles of Transforming Growth Factor-Beta-Induced Protein ig-h3, Peroxiredoxin-2, and NRF2 on Cervical Carcinogenesis.

Kontostathi G, Zoidakis J, Makridakis M, Lygirou V, Mermelekas G, Papadopoulos T, Vougas K, Vlamis-Gardikas A, Drakakis P, Loutradis D, Vlahou A, Anagnou NP, Pappa KI.

Biomed Res Int. 2017;2017:4180703. doi: 10.1155/2017/4180703. Epub 2017 Feb 2.

24.

Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca2+ signaling in T24M-based bladder cancer models.

Frantzi M, Klimou Z, Makridakis M, Zoidakis J, Latosinska A, Borràs DM, Janssen B, Giannopoulou I, Lygirou V, Lazaris AC, Anagnou NP, Mischak H, Roubelakis MG, Vlahou A.

Oncotarget. 2016 Oct 25;7(43):70750-70768. doi: 10.18632/oncotarget.12218.

25.

Desmin and αB-crystallin interplay in the maintenance of mitochondrial homeostasis and cardiomyocyte survival.

Diokmetzidou A, Soumaka E, Kloukina I, Tsikitis M, Makridakis M, Varela A, Davos CH, Georgopoulos S, Anesti V, Vlahou A, Capetanaki Y.

J Cell Sci. 2016 Oct 15;129(20):3705-3720. Epub 2016 Aug 26.

26.

Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring.

Kontostathi G, Zoidakis J, Anagnou NP, Pappa KI, Vlahou A, Makridakis M.

Expert Rev Proteomics. 2016 Aug;13(8):731-45. doi: 10.1080/14789450.2016.1210514. Review.

PMID:
27398979
27.

Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of -omics findings.

Latosinska A, Makridakis M, Frantzi M, Borràs DM, Janssen B, Mullen W, Zoidakis J, Merseburger AS, Jankowski V, Mischak H, Vlahou A.

Sci Rep. 2016 May 11;6:25619. doi: 10.1038/srep25619.

28.

High-Throughput LC-MS/MS Proteomic Analysis of a Mouse Model of Mesiotemporal Lobe Epilepsy Predicts Microglial Activation Underlying Disease Development.

Bitsika V, Duveau V, Simon-Areces J, Mullen W, Roucard C, Makridakis M, Mermelekas G, Savvopoulos P, Depaulis A, Vlahou A.

J Proteome Res. 2016 May 6;15(5):1546-62. doi: 10.1021/acs.jproteome.6b00003. Epub 2016 Apr 19.

PMID:
27057777
29.

Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study.

Frantzi M, van Kessel KE, Zwarthoff EC, Marquez M, Rava M, Malats N, Merseburger AS, Katafigiotis I, Stravodimos K, Mullen W, Zoidakis J, Makridakis M, Pejchinovski M, Critselis E, Lichtinghagen R, Brand K, Dakna M, Roubelakis MG, Theodorescu D, Vlahou A, Mischak H, Anagnou NP.

Clin Cancer Res. 2016 Aug 15;22(16):4077-86. doi: 10.1158/1078-0432.CCR-15-2715. Epub 2016 Mar 29.

30.

Comparative Analysis of Label-Free and 8-Plex iTRAQ Approach for Quantitative Tissue Proteomic Analysis.

Latosinska A, Vougas K, Makridakis M, Klein J, Mullen W, Abbas M, Stravodimos K, Katafigiotis I, Merseburger AS, Zoidakis J, Mischak H, Vlahou A, Jankowski V.

PLoS One. 2015 Sep 2;10(9):e0137048. doi: 10.1371/journal.pone.0137048. eCollection 2015. Erratum in: PLoS One. 2015;10(10):e0139268.

31.

Targeting the proteome of cellular fractions: focus on secreted proteins.

Latosinska A, Frantzi M, Mullen W, Vlahou A, Makridakis M.

Methods Mol Biol. 2015;1243:29-41. doi: 10.1007/978-1-4939-1872-0_2.

PMID:
25384738
32.

Biological sample collection for clinical proteomics: existing SOPs.

Lygirou V, Makridakis M, Vlahou A.

Methods Mol Biol. 2015;1243:3-27. doi: 10.1007/978-1-4939-1872-0_1. Review.

PMID:
25384737
33.

Redox proteomics: from residue modifications to putative biomarker identification by gel- and LC-MS-based approaches.

Mermelekas G, Makridakis M, Koeck T, Vlahou A.

Expert Rev Proteomics. 2013 Dec;10(6):537-49. doi: 10.1586/14789450.2013.855611. Review.

PMID:
24206227
34.

AF-MSCs fate can be regulated by culture conditions.

Zagoura DS, Trohatou O, Bitsika V, Makridakis M, Pappa KI, Vlahou A, Roubelakis MG, Anagnou NP.

Cell Death Dis. 2013 Apr 4;4:e571. doi: 10.1038/cddis.2013.93.

35.

Stem cells: insights into the secretome.

Makridakis M, Roubelakis MG, Vlahou A.

Biochim Biophys Acta. 2013 Nov;1834(11):2380-4. doi: 10.1016/j.bbapap.2013.01.032. Epub 2013 Jan 31. Review.

PMID:
23376432
36.

Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.

Katafigiotis I, Tyritzis SI, Stravodimos KG, Alamanis C, Pavlakis K, Vlahou A, Makridakis M, Katafigioti A, Garbis SD, Constantinides CA.

BJU Int. 2012 Dec;110(11 Pt B):E688-93. doi: 10.1111/j.1464-410X.2012.11501.x. Epub 2012 Sep 28.

37.

Biomarkers for bladder cancer aggressiveness.

Frantzi M, Makridakis M, Vlahou A.

Curr Opin Urol. 2012 Sep;22(5):390-6. doi: 10.1097/MOU.0b013e328356ad0e. Review.

PMID:
22825458
38.

Profilin 1 is a potential biomarker for bladder cancer aggressiveness.

Zoidakis J, Makridakis M, Zerefos PG, Bitsika V, Esteban S, Frantzi M, Stravodimos K, Anagnou NP, Roubelakis MG, Sanchez-Carbayo M, Vlahou A.

Mol Cell Proteomics. 2012 Apr;11(4):M111.009449. doi: 10.1074/mcp.M111.009449. Epub 2011 Dec 8.

39.

Human amniotic fluid-derived mesenchymal stem cells as therapeutic vehicles: a novel approach for the treatment of bladder cancer.

Bitsika V, Roubelakis MG, Zagoura D, Trohatou O, Makridakis M, Pappa KI, Marini FC, Vlahou A, Anagnou NP.

Stem Cells Dev. 2012 May 1;21(7):1097-111. doi: 10.1089/scd.2011.0151. Epub 2011 Oct 11.

PMID:
21988169
40.

Plasma proteomic analysis in obese and overweight prepubertal children.

Galata Z, Moschonis G, Makridakis M, Dimitraki P, Nicolaides NC, Manios Y, Bartzeliotou A, Chrousos GP, Charmandari E.

Eur J Clin Invest. 2011 Dec;41(12):1275-83. doi: 10.1111/j.1365-2362.2011.02536.x. Epub 2011 May 16.

PMID:
21569026
41.

In vitro and in vivo properties of distinct populations of amniotic fluid mesenchymal progenitor cells.

Roubelakis MG, Bitsika V, Zagoura D, Trohatou O, Pappa KI, Makridakis M, Antsaklis A, Vlahou A, Anagnou NP.

J Cell Mol Med. 2011 Sep;15(9):1896-913. doi: 10.1111/j.1582-4934.2010.01180.x.

42.

Comprehensive human urine standards for comparability and standardization in clinical proteome analysis.

Mischak H, Kolch W, Aivaliotis M, Bouyssié D, Court M, Dihazi H, Dihazi GH, Franke J, Garin J, Gonzalez de Peredo A, Iphöfer A, Jänsch L, Lacroix C, Makridakis M, Masselon C, Metzger J, Monsarrat B, Mrug M, Norling M, Novak J, Pich A, Pitt A, Bongcam-Rudloff E, Siwy J, Suzuki H, Thongboonkerd V, Wang LS, Zoidakis J, Zürbig P, Schanstra JP, Vlahou A.

Proteomics Clin Appl. 2010 Apr;4(4):464-78. doi: 10.1002/prca.200900189. Epub 2010 Feb 3.

43.

Secretome proteomics for discovery of cancer biomarkers.

Makridakis M, Vlahou A.

J Proteomics. 2010 Nov 10;73(12):2291-305. doi: 10.1016/j.jprot.2010.07.001. Epub 2010 Jul 15. Review.

PMID:
20637910
44.

Analysis of secreted proteins for the study of bladder cancer cell aggressiveness.

Makridakis M, Roubelakis MG, Bitsika V, Dimuccio V, Samiotaki M, Kossida S, Panayotou G, Coleman J, Candiano G, Anagnou NP, Vlahou A.

J Proteome Res. 2010 Jun 4;9(6):3243-59. doi: 10.1021/pr100189d.

PMID:
20423150
45.

Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer.

Makridakis M, Gagos S, Petrolekas A, Roubelakis MG, Bitsika V, Stravodimos K, Pavlakis K, Anagnou NP, Coleman J, Vlahou A.

Proteomics. 2009 Jan;9(2):287-98. doi: 10.1002/pmic.200800121.

PMID:
19105184
46.

Marked defects in the expression and glycosylation of alpha2-HS glycoprotein/fetuin-A in plasma from neonates with intrauterine growth restriction: proteomics screening and potential clinical implications.

Karamessinis PM, Malamitsi-Puchner A, Boutsikou T, Makridakis M, Vougas K, Fountoulakis M, Vlahou A, Chrousos G.

Mol Cell Proteomics. 2008 Mar;7(3):591-9. Epub 2007 Dec 7.

Supplemental Content

Loading ...
Support Center